Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles

Why It Matters

Identifying macrophage phenotype as a lever for protein‑corona control enables design of longer‑circulating, immune‑evasive nanocarriers, accelerating therapeutic delivery and reducing dosing burdens.

Key Takeaways

• M0 membranes reduce opsonin binding.
• M0@SMNs show lowest complement activation.
• Circulation half-life extended vs M1/M2.
• Hepatic clearance reduced for M0-coated particles.
• Protein corona masks ~40% membrane proteins.

Pulse Analysis

Cell‑membrane‑coated nanoparticles have emerged as a versatile platform for drug delivery, leveraging the native proteins and lipids of donor cells to mask synthetic cores from the immune system. Yet, once introduced into blood, these particles rapidly acquire a protein corona—a layer of adsorbed plasma proteins that can override the intended surface cues. The composition of this corona determines opsonin recognition, complement activation, and ultimately the biodistribution of the carrier. Understanding how the source cell’s phenotype shapes corona formation is therefore critical for engineering nanocarriers that truly evade clearance.

In the recent study, magnetic silica cores were cloaked with membranes from three macrophage phenotypes: naïve (M0), classically activated (M1) and alternatively activated (M2). Proteomic profiling revealed that M0‑derived coatings attracted the fewest immune opsonins such as C3, IgG and IgM, and triggered the lowest complement cascade. Nano‑flow cytometry showed that the protein corona concealed roughly 40 % of the original membrane proteins, but the M0 corona preserved enough “self” signals to avoid hepatic uptake. In vivo, M0@SMNs displayed markedly prolonged blood residence and reduced liver accumulation compared with M1@SMNs and M2@SMNs.

These findings position macrophage phenotype as a design lever for next‑generation nanomedicines. By selecting naïve macrophage membranes or engineering synthetic coatings that mimic the M0 corona profile, developers can achieve longer systemic circulation, lower dosing frequencies, and improved therapeutic indices for oncology, immunotherapy, and gene‑editing applications. Moreover, the study underscores the need to integrate proteomic corona analysis early in formulation pipelines, rather than relying solely on membrane characterization. Future work may explore scalable M0 membrane production and combine phenotype‑guided corona control with active targeting ligands for precision delivery.